Our educational activities are supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany; and additional support from FUJIFILM EUROPE GMBH, Fujifilm Italia S.p.A., FUJIFILM France S.A.S.
Overview
Management of patients with an impaired ovarian reserve or poor ovarian response (POR) to exogenous gonadotropin stimulation has challenged reproductive specialists for years. Apart from the limited understanding of its pathophysiology, there is wide heterogeneity in defining POR and overall disappointing outcomes in assisted reproductive technology (ART) cycles.
The 1st POSEIDON’s World Conference dissect the new POSEIDON criteria as a means to improve the management of patients exposed to assisted reproductive technology. The new criteria enable discussion of novel approaches catered specifically to patients with low prognosis during IVF, thereby offering better tools to optimise IVF success rates.
The program engages renowned international experts with vast clinical experience in constantly evolving subjects. The program aims to impart specific knowledge with focus on changing concepts or practices.
Learning Objectives
- With this conference, the participants will get acquainted with the state-of-the-art definition of impaired response to ovarian stimulation, comprehend the new low prognosis concept and its application in clinical practice, and individualise and manage women with expected or unexpected prognosis to ART as per the POSEIDON classification.
Target Audience
The program is intended for clinicians, embryologists, andrologists, scientists, and managers working in ART who wish to update their knowledge of advanced techniques and scientific innovations and understand best practices using evidence-based models of care.
Accreditation
This program has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 8 European CME credits (ECMEC®s).

This program has been accredited by the SWISS GYNECOLOGY SGGG with 12 CME credits.
The content of the following has been certified by the CPD Certification Service as conforming to continuing professional development principles, 1st Poseidon’s World Conference: The Low-Prognosis Patient In ART. Event: 9-10 September 2022

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Educational Resources
Previous Research Topic with 22 articles, downloadable as an eBook:
POSEIDON’s Stratification of “Low Prognosis Patients in ART”: The WHY, the WHAT, and the HOW

#POSEIDON2022 Gallery
Partnership
POSEIDON – Patient Oriented Strategies Encompassing IndividualizeD Oocyte Number
Algerian Society of Reproductive Medicine (SAMERE)
Brazilian Association of Assisted Reproduction (SBRA)
Brazilian Society of Human Reproduction (SBRH)
Italian Society of Fertility and Sterility (SIFES)
Portuguese Society of Reproductive Medicine (SPMR)
Spanish Fertility Society (SEF)
Educational Material
Free On-demand & E-learning
Watch the conference materials and the recorded streaming on our
E-learning platform
This program has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 8 European CME credits (ECMEC®s).
1st POSEIDON's World Conference: The low-Prognosis patient in ART
Held on 9-10 September, Lisbon
Final program
Accreditation
Language
Venue
Chairs
National Scientific Committee
Centro de Medicina da Reprodução – Ferticare
Braga, Portugal
Clínica Procriar
Porto , Portugal
Universidade de Coimbra
Facultade de Medicina
Coimbra, Portugal
AVA Clinic
Lisbon, Portuga
Centre for Reproductive Genetics Alberto Barros
Porto, Portugal
Hospital Lusíada
Lisbon, Portugal
CGR A.Barros
Porto, Portugal
International Scientific Committee
University Hospital of Copenhagen
Copenhagen, Denmark
MUHC Reproductive Center
McGill University
Montreal, QC, Canada
Rio de Janeiro State University
Vida Fertility Center
SBRH – Brazilian Society of Human Reproduction
Rio de Janeiro, Brazil
Ginefiv-GeneraLife
Madrid, Spain
St. Mary’s Hospital
British Fertility Society (BFS)
Manchester, UK
IVF Center Polyclinic Ibn Annafis – Sfax – Tunisia
Fertility Group of the STGO (Tunisian Society of obstetrics and gynecology)
Sfax, Tunisia
GENESIS – Center for Assistance in Human Reproduction
SBRA – Brazilian Society of Assisted Reproduction
Brasilia, Brazil
Tiziri IVF Center
Algiers, Algeria
King’s College London
London, UK
G.E.N.E.R.A. Centre for Reproductive Medicine
Rome, Italy
Edith Wolfson Medical Center
Sackler Faculty of Medicine, Tel-Aviv University
Tel-Aviv, Israel
Anatolia IVF and Women’s Health Center
Ankara, Turkey
Faculty
Klaus Bühler
Antonio La Marca
University of Modena and Reggio Emilia
Modena, Italy
Habib Midassi
Fertility Group of the STGO (Tunisian Society of obstetrics and gynecology)
Sfax, Tunisia
Ariel Weissman
Sackler Faculty of Medicine, Tel-Aviv University
Tel-Aviv, Israel
Final program
Agenda
08:00 Registration
08.30 MedE.A. (Medical Education Academy) Welcome
Robert Fischer, Germany
08.40 Local welcome
Pedro Xavier, Portugal
08.45 Introduction and objectives
Sandro C. Esteves, Brazil
08.55 Keynote Lecture:
Poseidon, myth and fertility in ancient Greece
Nina Papathanasopoulou, Greece
> Session I: The WHY and the WHAT
The Birth of Poseidon
Chairs: Filippo M. Ubaldi, Italy / Joaquin Llácer, Spain
09.30 L1 Why we need new criteria for low prognosis patients: a historical overview
Carlo Alviggi, Italy
09.50 L2 The POSEIDON criteria explained
Robert Fischer, Germany
10.10 Doctor’s perspective
Habib Midassi, Tunisia
10.20 Polling questions
Carlo Alviggi, Italy
10.25 Discussion
10.40 Coffee-break
>Session II: POSEIDON CRITERIA BIOMARKERS
The Nature of Poseidon
Chairs: Michael Dahan, Canada / Raj Mathur, UK
11.10 L3 Female age, oocyte and embryo competence: relevance for the POSEIDON criteria
Filippo M. Ubaldi, Italy
11.30 L4 Antral follicle count and anti-Mullerian hormone for patient classification under the POSEIDON criteria
Antonio La Marca, Italy
11.50 L5 The oocyte number and the relationship with low prognosis
Sesh K. Sunkara, UK
12.10 Clinician’s perspective on the role of a classification system for low
prognosis patients and female age and oocyte number in reproductive success
Raj Mathur, UK
12.20 Polling questions
Michaele Dahan, Canada
12.25 Discussion
12.45 Lunch
>Session III: POSEIDON METRICS
The Potency of Poseidon
Chairs: Robert Fischer, Germany / Amina Oumeziane, Algeria
14.15 L6 Ovarian hypo-response to COS and its proposed metrics: The FORT and the FOI
Alessandro Conforti, Italy
14.35 L7 The ART calculator: a validated tool to predict reproductive success in ART
Sandro C. Esteves, Brazil
14.55 Patient’s perspective
15.05 Polling questions
Robert Fischer, Germany
15.10 Discussion
15.30 Coffee-break
> Session IV: LESSONS FROM REAL-WORLD DATA RESEARCH
Stories of Poseidon
Chairs: Margarida Silvestre, Portugal; Sesh K. Sunkara, UK
15.50 L8 POSEIDON in clinical practice: prevalence and patient characteristics
Hakan Yarali, Turkey
16.10 L9 Cumulative Live Birth Rates in POSEIDON patients
Sandro C. Esteves, Brazil
16.20 Nutrition and Exercise
Maria Giulia Minasi, Italy
16.40 Polling questions
Sesh Sunkara, UK
16.45 Discussion
17.05 Closing of the first day
Carlo Alviggi, Italy
> Session V: Clinical Utility
Poseidon as Protector
Chairs: Ariel Weissman, Israel/ Carlo Alviggi, Italy
09.00 Introduction to the second day
Sandro C. Esteves, Brazil
09.05 The protection of nature by Archipelagos
Sandro C Esteves, Brazil
09.10 L10 Management strategies in POSEIDON groups 1 and 2 patients
Klaus Bühler, Germany
09.30 Polling questions, case scenarios and panel discussion
Presenter: K. Bühler
Panelists: C. Alviggi; A. La Marca; J. Llacer A. Oumeziane; A. Weissman
10.05 L11 Management strategies in POSEIDON groups 3 and 4 patients
Robert Fischer, Germany
10.25 Polling questions, case scenarios and panel discussion
Presenter: R. Fischer
Panelists: F. M. Ubaldi; M. Dahan; H. Yarali; S. Sunkara; A. Weissman
11.00 Nurse’s perspective
Valerie Peddie, UK
11.05 Coffee-break
> Session VI: Research and Future Perspectives
Poseidon the Earthshaker
Chairs: Pedro Xavier, Portugal / Sandro C. Esteves, Brazil
11.40 L12 The POSORT guidelines: improving study design and reporting of clinical trials
Raoul Orvieto, Israel
12.00 L13 Frontiers in Endocrinology research topic
Claus Yding Andersen, Denmark
12.05 L14 The POSEIDON group: what did we achieve and what’s next?
Carlo Alviggi, Italy
12.25 Panel discussion
R. Orvieto; C. Alviggi; H. Yarali; F. M. Ubaldi; M. Dahan; S. Sunkara
12.55 Concluding remarks
Robert Fischer, Germany
13.00 End of the conference
Pedro Xavier, Portugal
13.05 Closing Lunch